Intensity Therapeutics, Inc. reported a net loss of $2.5 million for the second quarter ended June 30, 2025, representing a 50% improvement from the $5.0 million net loss in the same period of 2024. Research and development expenses decreased to $1.5 million from $3.6 million, primarily due to lower INVINCIBLE-3 Study costs following the pause in new enrollment. General and administrative expenses also declined to $1.2 million from $1.5 million, attributed to favorable insurance terms and administrative efficiencies.
As of June 30, 2025, cash and cash equivalents totaled $2.2 million. Since the beginning of the second quarter of 2025, the company raised an aggregate of $11.3 million in gross proceeds, with net proceeds of approximately $10.1 million, through public offerings and At-the-Market offerings. This capital has extended the company's cash runway into the second half of 2026.
On the clinical front, the INVINCIBLE-4 Phase 2 study for triple-negative breast cancer is recruiting in Switzerland and France, with early imaging data showing a substantial decrease in tumor activity after two doses of INT230-6. The Phase 3 INVINCIBLE-3 study for soft tissue sarcoma remains paused for new enrollment due to funding, though enrolled patients continue treatment. The company also announced a collaboration with breast cancer survivor Christine Handy to raise patient awareness.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.